PULM
Pulmatrix, Inc.
Price Chart
Latest Quote
$1.46
-0.04 (-2.67%)
Current Price
| Previous Close | $1.50 |
| Open | $1.48 |
| Day High | $1.51 |
| Day Low | $1.41 |
| Volume | 1,406,897 |
Stock Information
| Shares Outstanding | 3.65M |
| Cash Equivalents | $3.32M |
| Net Income | $-4.53M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.33M |
| EPS (TTM) | $-1.21 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.96M |
| Income | $-4.53M |
| Book/sh | $0.72 |
| Cash/sh | $0.91 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 3.67 |
| Current Ratio | 4.96 |
Returns & Margins
| ROA | -45.97% |
| ROE | -84.30% |
Ownership
| Insider Ownership | 0.74% |
| Institutional Ownership | 9.02% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.32 |
| P/B | 2.02 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.38 |
| SMA50 | $1.33 |
| SMA200 | $2.96 |
| RSI | 57.78 |
| ATR | 0.0996 |
| Shares Float | 3.65M |
| Short Float | 0.69% |
| Short Ratio | 1.49 |
| Volatility | 1.94 |
| Rel Volume | 14.49 |
Performance History
| Week | +5.80% |
| Month | +15.87% |
| Quarter | -32.09% |
| 6 Months | -64.39% |
| YTD | -35.40% |
| Year | -82.11% |
| 3 Years | -45.32% |
| 5 Years | -93.60% |
| 10 Years | -99.67% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.46 | 1,406,900 |
| 2026-06-17 | $1.50 | 12,700 |
| 2026-06-16 | $1.49 | 60,200 |
| 2026-06-15 | $1.41 | 9,800 |
| 2026-06-12 | $1.40 | 23,700 |
| 2026-06-11 | $1.38 | 12,300 |
| 2026-06-10 | $1.37 | 3,000 |
| 2026-06-09 | $1.38 | 46,300 |
| 2026-06-08 | $1.42 | 141,700 |
| 2026-06-05 | $1.33 | 32,200 |
| 2026-06-04 | $1.32 | 13,300 |
| 2026-06-03 | $1.29 | 13,300 |
| 2026-06-02 | $1.32 | 29,600 |
| 2026-06-01 | $1.39 | 22,700 |
| 2026-05-29 | $1.39 | 12,100 |
| 2026-05-28 | $1.38 | 21,000 |
| 2026-05-27 | $1.36 | 14,400 |
| 2026-05-26 | $1.34 | 18,300 |
| 2026-05-22 | $1.34 | 23,100 |
| 2026-05-21 | $1.37 | 24,900 |
| 2026-05-20 | $1.27 | 18,100 |
| 2026-05-19 | $1.26 | 6,200 |
About Pulmatrix, Inc.
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $7,806,000 | $7,298,000 | $6,071,000 |
| Operating Revenue | $0 | $7,806,000 | $7,298,000 | $6,071,000 |
| Expenses | ||||
| Total Expenses | $5,169,000 | $14,951,000 | $22,038,000 | $25,018,000 |
| Other Income Expense | $-137,000 | $-2,881,000 | $-248,000 | $-198,000 |
| Other Non Operating Income Expenses | $-204,000 | $-196,000 | $-248,000 | $-198,000 |
| Net Non Operating Interest Income Expense | $144,000 | $467,000 | $867,000 | $309,000 |
| Operating Expense | $5,169,000 | $14,951,000 | $22,038,000 | $25,018,000 |
| General And Administrative Expense | $5,131,000 | $7,785,000 | $6,520,000 | $6,778,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-5,162,000 | $-9,559,000 | $-14,121,000 | $-18,836,000 |
| Net Interest Income | $144,000 | $467,000 | $867,000 | $309,000 |
| Interest Income | $144,000 | $467,000 | $867,000 | $309,000 |
| Normalized Income | $-5,229,000 | $-6,874,000 | $-14,121,000 | $-18,836,000 |
| Net Income From Continuing And Discontinued Operation | $-5,162,000 | $-9,559,000 | $-14,121,000 | $-18,836,000 |
| Total Operating Income As Reported | $-5,169,000 | $-9,763,000 | $-14,740,000 | $-18,947,000 |
| Net Income Common Stockholders | $-5,162,000 | $-9,559,000 | $-14,121,000 | $-18,836,000 |
| Net Income | $-5,162,000 | $-9,559,000 | $-14,121,000 | $-18,836,000 |
| Net Income Including Noncontrolling Interests | $-5,162,000 | $-9,559,000 | $-14,121,000 | $-18,836,000 |
| Net Income Continuous Operations | $-5,162,000 | $-9,559,000 | $-14,121,000 | $-18,836,000 |
| Pretax Income | $-5,162,000 | $-9,559,000 | $-14,121,000 | $-18,836,000 |
| Special Income Charges | $0 | $-2,618,000 | $0 | $0 |
| Interest Income Non Operating | $144,000 | $467,000 | $867,000 | $309,000 |
| Operating Income | $-5,169,000 | $-7,145,000 | $-14,740,000 | $-18,947,000 |
| Per Share | ||||
| Diluted EPS | $-1.41 | $-2.62 | $-3.87 | $-5.46 |
| Basic EPS | $-1.41 | $-2.62 | $-3.87 | $-5.46 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,236,000 | $-4,025,000 | $-13,265,000 | $-17,402,000 |
| Total Unusual Items | $67,000 | $-2,685,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $67,000 | $-2,685,000 | $0 | $0 |
| Reconciled Depreciation | $0 | $435,000 | $1,475,000 | $1,545,000 |
| EBITDA (Bullshit earnings) | $-5,169,000 | $-6,710,000 | $-13,265,000 | $-17,402,000 |
| EBIT | $-5,169,000 | $-7,145,000 | $-14,740,000 | $-18,947,000 |
| Diluted Average Shares | $3,652,285 | $3,652,285 | $3,651,911 | $3,447,701 |
| Basic Average Shares | $3,652,285 | $3,652,285 | $3,651,911 | $3,447,701 |
| Diluted NI Availto Com Stockholders | $-5,162,000 | $-9,559,000 | $-14,121,000 | $-18,836,000 |
| Gain On Sale Of Business | $0 | $-2,618,000 | $0 | - |
| Gain On Sale Of Security | $67,000 | $-67,000 | - | - |
| Research And Development | $38,000 | $7,166,000 | $15,518,000 | $18,240,000 |
| Selling General And Administration | $5,131,000 | $7,785,000 | $6,520,000 | $6,778,000 |
| Other Gand A | $5,131,000 | $7,785,000 | $6,520,000 | $6,778,000 |
| Impairment Of Capital Assets | - | - | - | $0 |
| Preferred Stock Dividends | - | - | - | - |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,810,000 | $8,947,000 | $17,995,000 | $31,109,000 |
| Total Assets | $4,139,000 | $9,943,000 | $33,958,000 | $40,953,000 |
| Total Non Current Assets | $10,000 | $23,000 | $13,115,000 | $2,806,000 |
| Other Non Current Assets | $10,000 | $23,000 | $1,648,000 | $1,861,000 |
| Current Assets | $4,129,000 | $9,920,000 | $20,843,000 | $38,147,000 |
| Other Current Assets | $34,000 | $180,000 | $372,000 | $166,000 |
| Prepaid Assets | $7,000 | $219,000 | $370,000 | $902,000 |
| Cash Cash Equivalents And Short Term Investments | $4,088,000 | $9,521,000 | $19,173,000 | $35,628,000 |
| Cash And Cash Equivalents | $4,088,000 | $9,521,000 | $19,173,000 | $35,628,000 |
| Receivables | - | $0 | $928,000 | $1,298,000 |
| Accounts Receivable | - | $0 | $928,000 | $1,298,000 |
| Restricted Cash | - | - | $0 | $153,000 |
| Goodwill And Other Intangible Assets | - | - | - | - |
| Debt | ||||
| Total Debt | - | $0 | $8,756,000 | $857,000 |
| Long Term Debt And Capital Lease Obligation | - | $0 | $8,327,000 | $0 |
| Current Debt And Capital Lease Obligation | - | - | $429,000 | $857,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $329,000 | $996,000 | $15,963,000 | $9,844,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $67,000 | $12,054,000 | $4,822,000 |
| Derivative Product Liabilities | $0 | $67,000 | $0 | - |
| Current Liabilities | $329,000 | $929,000 | $3,909,000 | $5,022,000 |
| Other Current Liabilities | $14,000 | $71,000 | $99,000 | $33,000 |
| Payables And Accrued Expenses | $315,000 | $858,000 | $2,763,000 | $2,793,000 |
| Payables | $272,000 | $809,000 | $1,915,000 | $1,188,000 |
| Accounts Payable | $272,000 | $809,000 | $1,915,000 | $1,188,000 |
| Non Current Deferred Liabilities | - | $0 | $3,727,000 | $4,822,000 |
| Current Deferred Liabilities | - | $0 | $618,000 | $1,339,000 |
| Equity | ||||
| Common Stock Equity | $3,810,000 | $8,947,000 | $17,995,000 | $31,109,000 |
| Total Equity Gross Minority Interest | $3,810,000 | $8,947,000 | $17,995,000 | $31,109,000 |
| Stockholders Equity | $3,810,000 | $8,947,000 | $17,995,000 | $31,109,000 |
| Retained Earnings | $-302,318,000 | $-297,156,000 | $-287,597,000 | $-273,476,000 |
| Preferred Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $3,652,285 | $3,652,285 | $3,652,285 | $3,639,185 |
| Share Issued | $3,652,285 | $3,652,285 | $3,652,285 | $3,639,185 |
| Tangible Book Value | $3,810,000 | $8,947,000 | $17,995,000 | $31,109,000 |
| Invested Capital | $3,810,000 | $8,947,000 | $17,995,000 | $31,109,000 |
| Working Capital | $3,800,000 | $8,991,000 | $16,934,000 | $33,125,000 |
| Total Capitalization | $3,810,000 | $8,947,000 | $17,995,000 | $31,109,000 |
| Additional Paid In Capital | $306,128,000 | $306,103,000 | $305,592,000 | $304,585,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Accrued Expenses | $43,000 | $49,000 | $848,000 | $1,605,000 |
| Capital Lease Obligations | - | $0 | $8,756,000 | $857,000 |
| Non Current Deferred Revenue | - | $0 | $3,727,000 | $4,822,000 |
| Long Term Capital Lease Obligation | - | $0 | $8,327,000 | $0 |
| Current Deferred Revenue | - | $0 | $618,000 | $1,339,000 |
| Current Capital Lease Obligation | - | $0 | $429,000 | $857,000 |
| Net PPE | - | $0 | $11,467,000 | $945,000 |
| Accumulated Depreciation | - | $0 | $-1,736,000 | $-2,748,000 |
| Gross PPE | - | $0 | $13,203,000 | $3,693,000 |
| Leases | - | $0 | $0 | $664,000 |
| Construction In Progress | - | $0 | $600,000 | $0 |
| Machinery Furniture Equipment | - | $0 | $638,000 | $492,000 |
| Properties | - | $0 | $0 | $0 |
| Other Properties | - | - | $11,965,000 | $2,537,000 |
| Goodwill | - | - | - | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-5,433,000 | $-11,114,000 | $-16,661,000 | $-19,442,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-5,433,000 | $-10,716,000 | $-15,985,000 | $-19,356,000 |
| Cash Flow From Continuing Operating Activities | $-5,433,000 | $-10,716,000 | $-15,985,000 | $-19,356,000 |
| Operating Gains Losses | $-67,000 | $2,685,000 | $8,000 | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-398,000 | $-676,000 | $-86,000 |
| Cash Flow From Continuing Investing Activities | $0 | $-398,000 | $-676,000 | $-86,000 |
| Capital Expenditure | - | $-398,000 | $-676,000 | $-86,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | - | $0 | $53,000 | $1,382,000 |
| Financing Cash Flow | - | $0 | $53,000 | $1,230,000 |
| Cash Flow From Continuing Financing Activities | - | $0 | $53,000 | $1,230,000 |
| Net Common Stock Issuance | - | $0 | $53,000 | $1,382,000 |
| Common Stock Issuance | - | $0 | $53,000 | $1,382,000 |
| Repurchase Of Capital Stock | - | - | - | $-152,000 |
| Net Other Financing Charges | - | - | - | $-152,000 |
| Net Preferred Stock Issuance | - | - | - | $-152,000 |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $4,098,000 | $9,531,000 | $20,645,000 | $37,253,000 |
| Beginning Cash Position | $9,531,000 | $20,645,000 | $37,253,000 | $55,465,000 |
| Changes In Cash | $-5,433,000 | $-11,114,000 | $-16,608,000 | $-18,212,000 |
| Net PPE Purchase And Sale | $0 | $-398,000 | $-676,000 | $-86,000 |
| Purchase Of PPE | $0 | $-398,000 | $-676,000 | $-86,000 |
| Change In Working Capital | $-229,000 | $-4,788,000 | $-4,301,000 | $-3,179,000 |
| Change In Other Current Liabilities | $0 | $-333,000 | $-3,041,000 | $-1,431,000 |
| Change In Other Current Assets | $13,000 | $163,000 | $213,000 | $-389,000 |
| Change In Payables And Accrued Expense | $-600,000 | $-1,544,000 | $-353,000 | $916,000 |
| Change In Accrued Expense | $-63,000 | $-438,000 | $-1,080,000 | $405,000 |
| Change In Payable | $-537,000 | $-1,106,000 | $727,000 | $511,000 |
| Change In Account Payable | $-537,000 | $-1,106,000 | $727,000 | $511,000 |
| Change In Prepaid Assets | $358,000 | $343,000 | $326,000 | $-197,000 |
| Change In Receivables | $0 | $928,000 | $370,000 | $-1,231,000 |
| Changes In Account Receivables | $0 | $928,000 | $370,000 | $-1,231,000 |
| Stock Based Compensation | $25,000 | $511,000 | $954,000 | $1,114,000 |
| Depreciation Amortization Depletion | $0 | $435,000 | $1,475,000 | $1,545,000 |
| Depreciation And Amortization | $0 | $435,000 | $1,475,000 | $1,545,000 |
| Depreciation | $0 | $435,000 | $1,475,000 | $1,545,000 |
| Gain Loss On Investment Securities | $-67,000 | $67,000 | - | - |
| Net Income From Continuing Operations | $-5,162,000 | $-9,559,000 | $-14,121,000 | $-18,836,000 |
| Change In Other Working Capital | - | $-4,345,000 | $-1,816,000 | $-847,000 |
| Gain Loss On Sale Of PPE | - | - | $8,000 | $0 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
| Preferred Stock Payments | - | - | - | $-152,000 |
| Asset Impairment Charge | - | - | - | $0 |
| Repayment Of Debt | - | - | - | - |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-18